Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- DS-8201 Shows Overall Response Rate of 15.8% in Patients with Colorectal Cancer in Japan-US PI Study: Daiichi Sankyo
October 23, 2018
- Hisamitsu Begins Japan PII Study of Hyperhidrosis Treatment
October 23, 2018
- Eisai, MSD Begin Joint Information Provisioning for Lenvima in Japan
October 23, 2018
- Mitsubishi Tanabe Teams Up with Bioventure for Novel Antibody Drug Discovery Research in Autoimmune Diseases
October 23, 2018
- Mundipharma Shooting for Japan Sales of US$500 Million in 10 Years: CEO
October 22, 2018
- Daiichi Sankyo Begins 1st-in-Human Trial for AXL Inhibitor
October 22, 2018
- JCR’s Hunter Syndrome Drug Grabs FDA’s Orphan Status
October 22, 2018
- Eisai, Keio Univ. Identify Candidate Compound for Parkinson’s Disease Employing iPS Cells
October 22, 2018
- Prescribers Asked to Stop New Enbrel Biosimilar Use as Maker Can’t Keep Up with Demand
October 19, 2018
- Takeda Earns Japan Clearance for Shire Acquisition
October 19, 2018
- Asahi Kasei Obtains Patent License for iPS Cell-Derived Cartilage Regeneration Technology
October 18, 2018
- Sumitomo Dainippon to Invest in, Conduct Joint R&D with Cyborg Tech Startup
October 18, 2018
- Nippon Shinyaku Seeks Japan Approval for Hepatic VOD Treatment Defibrotide
October 18, 2018
- Shionogi Launches New Manufacturing Subsidiary, Commencing Operations in April Next Year
October 18, 2018
- Eisai’s Insomnia Treatment Lemborexant Smashes Primary Target in Long-Term PIII Study
October 18, 2018
- Daiichi Sankyo Files Quizartinib for AML in Japan
October 18, 2018
- JAK Inhibitor Battle for Atopic Dermatitis Intensifying, 1st Japan Filing Might Be Near
October 17, 2018
- Eisai Seals Latin America Pact for Belviq
October 17, 2018
- Teva Takeda Launches Voluntary Recall for Taxotere Generics
October 17, 2018
- Chugai’s Satralizumab Cuts Relapse Risk of Neuromyelitis Optica Spectrum Disorder
October 16, 2018
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…